NORWALK, Conn., Dec. 6, 2019 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) today announced that 34 abstracts will be presented at the 61st American Society of Hematology Annual Meeting in Orlando from December 7-10. Twenty-two of the presentations include data from the highly influential MMRF CoMMpass StudySM, which represents the largest genomic data set of any cancer and is one of the most widely published studies in multiple myeloma. The remaining 12 abstracts include data from MMRF-supported research programs and presentations on clinical trials supported by the Multiple Myeloma Research Consortium (MMRC).
"Collaborative research efforts have led to great progress in the treatment and understanding of multiple myeloma," said Daniel Auclair, PhD, Chief Scientific Officer of the MMRF. "Through the CoMMpass Study, we are supplying myeloma researchers world-wide with information they need to formulate new hypotheses and generate discoveries around the genetic drivers of myeloma, enabling us to better personalize care and treatment expectations as well as speed the discovery and development of new and novel therapies."
CoMMpass Study highlights include:
- A crowd-sourcing effort using CoMMpass data that identified PHF19 as a gene that is strongly associated with disease progression
- Characterization of new genomic markers that can help predict high-risk disease
- Discovery of genomic alterations associated with the development of plasma cell leukemia
- Identification of epigenomic alterations that are prognostic of clinical outcomes
- Description of genomic differences that may account for increased incidence of multiple myeloma in African Americans; a separate study on myeloma in African Americans – using samples from our MMRF tissue bank – has helped identify several markers that are significantly associated with myeloma risk in African Americans
Additionally, the MMRF's ongoing investment to advance immunotherapy approaches, as well as research efforts focused on the use of minimal residual disease (MRD) and early disease, have resulted in several important findings.
New immunotherapy data include:
- An analysis of CoMMpass immune data revealed that PD-1/PD-L1 checkpoint inhibitors may be effective for a subtype of patients with high mutation burden
- Novel findings from an MMRF-supported study on CAR T-cell therapy in combination with personalized vaccines
New investigation of the use of MRD testing includes:
- A landmark phase II MMRC study, which is the first to use MRD measurement to directly compare the efficacy of lenalidomide versus ixazomib maintenance therapy after autologous stem cell transplant and consolidation with lenalidomide, ixazomib and dexamethasone in newly diagnosed myeloma patients
Early disease breakthroughs include:
- State of the art analyses of MMRC tissue bank samples from smoldering multiple myeloma (SMM) patients reveal new biomarkers that may predict progression to symptomatic myeloma
- Work from the Prevention Project, supported by the Perelman Family Foundation, offers new insights into the mechanisms of progression, including a potential new tool for use in monitoring SMM progression status
- Early data from an MMRC supported Phase II study of daratumumab in patients with early disease (high-risk MGUS/low-risk smoldering myeloma) shows daratumumab is very well-tolerated, with the majority of patients exhibiting a response and no patients progressing to active disease
For complete data on MMRF and MMRC abstracts being presented at the 61st ASH Annual Meeting please contact Mary DeRome at [email protected].
About the MMRF CoMMpass StudySM
The MMRF CoMMpass Study is a longitudinal study of patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF's Personalized Medicine Initiative, the study is collecting and analyzing tissue samples, clinical data and genetic information from 1,000 newly diagnosed multiple myeloma patients for at least eight years. The CoMMpass Study was made possible by a $40M investment by the MMRF.
The MMRF CoMMpass Study opened in July of 2011 and now includes 1,150 patients from 76 sites in the United States, Canada and European Union. Data from the MMRF CoMMpass Study is made available to researchers via the MMRF's Researcher Gateway (http://research.themmrf.org), an online, open-access portal designed to make key genomic and clinical data available for additional study. The MMRF CoMMpass Study is being supported through a public-private partnership of patient donors and industry partners, including Takeda Oncology, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. and Janssen Diagnostics. Additional collaborating research partners include the Translational Genomics Research Institute, Van Andel Research Institute and GNS Healthcare.
Please visit www.themmrf.org/research-partners/the-commpass-study to learn more about the study.
About Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,770 adults (16,400 men and 14,730 women) in the United States will be diagnosed with MM in 2019 and an estimated 12,770 people are predicted to die from the disease. The five-year survival rate for MM is approximately 47%, versus 31% in 1999.
About the Multiple Myeloma Research Foundation (MMRF)
A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 11 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Consortium (MMRC) is a 509 (a) (3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from the MMRC offices in Norwalk, Conn., and comprises 25 member institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Beth Israel Deaconess, Brigham and Women's Hospital, Mayo Clinic (Jacksonville, Rochester and Scottsdale), Baylor Charles A. Sammons Cancer Center at Dallas, Barbara Ann Karmanos Cancer Institute, City of Hope, Emory University's Winship Cancer Institute, Levine Cancer Institute, The John Theurer Cancer Center at Hackensack University Medical Center, Memorial Sloan Kettering, Mount Sinai Icahn School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of Arkansas for Medical Sciences, University of California, San Francisco, University of Chicago, University of Michigan, UT Southwestern, Virginia Cancer Specialists and Washington University in St. Louis.
Anne Quinn Young, MPH
Senior Vice President of Marketing and Communications
Multiple Myeloma Research Foundation (MMRF)
SOURCE Multiple Myeloma Research Foundation